Jeffrey Ward

Medicine & Life Sciences

1. Adenocarcinoma of Lung 12%
2. Antibodies 10%
3. Antigens 20%
4. atezolizumab 18%
5. B-Lymphocytes 9%
6. Biomarkers 9%
7. Brentuximab Vedotin 19%
8. Carrier Proteins 10%
9. CD226 antigen 11%
10. Cell Communication 23%
11. Cell- and Tissue-Based Therapy 11%
12. Circulating Tumor DNA 34%
13. Cross-Priming 9%
14. Dendritic Cells 11%
15. DNA Damage 10%
16. DNA Fingerprinting 14%
17. Epitopes 12%
18. Glioblastoma 11%
19. HIV 43%
20. HIV Infections 12%
21. HIV-1 67%
22. HLA-C Antigens 17%
23. Immunity 21%
24. Immunotherapy 54%
25. In Vitro Techniques 7%
26. Lenalidomide 15%
27. Ligands 26%
28. Lung Neoplasms 10%
29. Lymphoma, Large B-Cell, Diffuse 13%
30. Major Histocompatibility Complex 14%
31. Mutation 11%
32. Natural Killer Cell Receptors 20%
33. Natural Killer Cells 90%
34. Neon 9%
35. Neoplasm Antigens 13%
36. Neoplasms 59%
37. Non-Small Cell Lung Carcinoma 23%
38. Primate Lentiviruses 12%
39. Proteins 7%
40. Radiation 17%
41. ramucirumab 19%
42. Recycling 13%
43. Sarcoma 16%
44. Small Cell Lung Carcinoma 14%
45. Smokers 10%
46. T-Lymphocytes 100%
47. Therapeutics 17%
48. Tumor Microenvironment 17%
49. Tumor-Infiltrating Lymphocytes 15%
50. vpr Gene Products 19%